- GSK, Immunocore enter deal worth up to $508M
GlaxoSmithKline and Immunocore agreed to collaborate in the discovery and development of drugs using the latter's ImmTACs technology. Immunocore will handle preclinical development and initial clinical studies while GSK will assume the remaining development and commercialization. GSK could pay Immunocore up to about $211 million in preclinical milestone fees and as much as about $297 million in development and commercial milestone payments plus sales royalties. Last month, Genentech and Immunocore formed a similar partnership. Reuters (7/9), Genetic Engineering & Biotechnology News (7/9)        | Stop banking and start building with GE Capital, Healthcare Financial Services
At GE Capital, we're not just bankers, we're builders. Supporting the growth of life science companies, large and small, as a reliable source of financing is our mission at GE Capital, Healthcare Financial Services. With in-depth industry experience and expertise, our dedicated Life Science Finance team has provided over $1.7 billion in financing over the past 10 years. Stop just banking. And start building. Learn more. | |
- GSK submits melanoma drug combo for FDA approval
GlaxoSmithKline filed an application with the FDA for approval to market a combination of dabrafenib and trametinib as a treatment for melanoma. The application is supported by data from a Phase I/II trial. Dabrafenib and trametinib, sold under the brand names Tafinlar and Mekinist, respectively, were individually approved by the FDA in May. Reuters (7/9) - Researchers use genetics to develop cancer meds from bacteria
Researchers at the University of East Anglia are working on new cancer treatments that address a fundamental cause of chemotherapy resistance. The research centers on a type of antibiotic produced by Streptomyces bacteria, which live symbiotically with leaf cutter ants. "We're using genetics to understand how the drugs are made in the bacteria so we can tweak the characteristics in favor of anti-cancer action, whilst protecting healthy cells," lead researcher Matt Hutchings said. "We want to make Streptomyces into a factory to produce a new type of chemotherapy drug on a large scale." Business Weekly (U.K.) (7/8)  | Earn your MBA online from Northeastern University
Earn your MBA from an AACSB-accredited university that was one of the first to offer its MBA in an online format. Customize your MBA - pursue one of 8 specializations: Finance, Healthcare Management, High Technology Management, Innovation Entrepreneurship, International Management, Marketing, Operations & Supply Chain Management, or Sustainability.
Get started>> |
 - N.C. cancer Dx firm obtains $2.5M in funding round
Durham, N.C.-based GeneCentric Diagnostics has raised $2.5 million in financing, which CEO Myla Lai-Goldman said would go toward the company's efforts to transform cancer research into clinical diagnostics. The company's first product is a diagnostic tool called the Lung Subtype Platform, which uses tumor genes to classify lung-cancer patients into subtypes and help clinicians identify the best therapy options. MedCityNews.com (7/8)  | Analyst brief: Axendia: Lowering the Cost of Healthcare from the Inside Out
Healthcare administrators are seeking ways to manage a mix of Clinical, Biomedical, Facilities, Engineering and Health IT assets. Learn how Healthcare Executives are leveraging an integrated Enterprise Asset Management solution to enhance patient care and improve clinical outcomes, reduce costs and ensure compliance. |
 | Food & Agriculture |  |  | | | Industrial & Environmental | | | | - Researchers bank on algae as next biofuel source
Researchers of alternative energy sources are banking on algae's potential to replace crude oil, although their work is in an early and expensive phase. Advocates say the material is highly optimal, as it is grown in saltwater and is carbon neutral. The federal government supports the development of this biofuel, with President Barack Obama allotting $30 million in funding for research last year. CBS MoneyWatch (7/8) | News from BIO | | | | - Save on energy costs through BIO's newest cost-savings program
BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy suppliers for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more.
| SmartQuote | | | |  | Difficulties are just things to overcome, after all."
--Ernest Shackleton,
Antarctic explorer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, July 09, 2013
- Monday, July 08, 2013
- Friday, July 05, 2013
- Wednesday, July 03, 2013
- Tuesday, July 02, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment